Independent directory Public ClinicalTrials.gov records United States
Location Directory

Clinical trials in Dallas, Texas

This page shows live ClinicalTrials.gov search results for Dallas, Texas, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
13791
Shown on this page
12
Current sort
Recently updated
Location scope
Dallas, TX
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Dallas, Texas. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 337–348 of 13,791 matching trials in Dallas, TX.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Dallas

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Conditions
Advanced Cancer, Metastatic Cancer
Interventions
Mocaciclib (Q901), KEYTRUDA® (pembrolizumab), Fulvestrant
Drug
Lead sponsor
Qurient Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
7
States / cities
Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 4 more
Conditions
Partial Lipodystrophy
Interventions
metreleptin, Placebo
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
12 Years and older
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
13
States / cities
Birmingham, Alabama • Sacramento, California • Boca Raton, Florida + 9 more
Conditions
Ischemic Stroke, Sleep Apnea, Sleep Apnea, Obstructive, Stroke, CPAP, Telemedicine, Home Sleep Apnea Test, Randomized Clinical Trial, Multicenter Trial
Interventions
CPAP
Device
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
1,892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
116
States / cities
Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 94 more
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Pembrolizumab, Cisplatin, Carboplatin, Pemetrexed, Gemcitabine, Paclitaxel, Intismeran autogene, Placebo
Biological · Drug · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2038
U.S. locations
54
States / cities
Gilbert, Arizona • Tucson, Arizona • Fullerton, California + 42 more
Conditions
Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Interventions
BI 4015092, Cetuximab
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
3
States / cities
New Haven, Connecticut • Dallas, Texas • Houston, Texas
Conditions
Multiple Sclerosis
Interventions
Frexalimab, Placebo, MRI contrast-enhancing agents
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 60 Years
Enrollment
943 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
79
States / cities
Homewood, Alabama • Scottsdale, Arizona • Berkeley, California + 68 more
Conditions
Primary Membranous Nephropathy
Interventions
Felzartamab, Tacrolimus, Standard of Care IST
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 80 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
16
States / cities
Huntsville, Alabama • Fresno, California • Los Angeles, California + 12 more
Conditions
Metabolic Dysfunction-Associated Steatohepatitis, MASH
Interventions
ALN-CIDEB, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
22
States / cities
Tucson, Arizona • Pasadena, California • Rialto, California + 16 more
Active, not recruiting Phase 3 Interventional

Bionic Pancreas in CFRD

NCT06449677
Conditions
Cystic Fibrosis-related Diabetes
Interventions
iLet Bionic Pancreas System (BP), Usual Care (UC)
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
14 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Aurora, Colorado • New Haven, Connecticut • Atlanta, Georgia + 13 more
Conditions
Breast Cancer, Metastatic
Interventions
Evorpacept (ALX148), Trastuzumab, Paclitaxel, Capecitabine, Eribulin, Gemcitabine, Vinorelbine
Drug
Lead sponsor
ALX Oncology Inc.
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
28
States / cities
Phoenix, Arizona • Tucson, Arizona • Duarte, California + 24 more
Conditions
Obesity, Overweight
Interventions
Maridebart cafraglutide, Autoinjector
Drug · Device
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
24
States / cities
San Diego, California • Miami, Florida • Orlando, Florida + 17 more
Conditions
Homocystinuria
Interventions
Pegtibatinase, Placebo
Drug · Other
Lead sponsor
Travere Therapeutics, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
13
States / cities
Phoenix, Arizona • New Haven, Connecticut • Atlanta, Georgia + 10 more